Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective.

ABSTRACT:

Introduction

We described patients' and care partners' experiences with Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker testing and result disclosure in routine care.

Methods

IMPACT-AD BC is an observational study of clinic patients who underwent AD CSF biomarker testing as part of their routine medical care (n = 142). In the personal utility arm of the study, semi-structured phone interviews were conducted with a subset of patients (n = 34), and separately with their care partners (n = 31). Post-disclosure interviews were conducted ∼1 month and ∼6 months after biomarker result disclosure and investigated the patients' decision-making process around testing, impact of receiving results, wellness and lifestyle changes, and future planning.

SUBMITTER: Patel KJ 

PROVIDER: S-EPMC10999946 | biostudies-literature | 2024 Apr-Jun

REPOSITORIES: biostudies-literature